The Mountain View, Calif.-based company posted profits of $837,000, or 2¢ per share, on sales of $180.9 million for the 3 months ended June 30, for sales growth of 4.6% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were 2¢, meeting consensus on The Street, where analysts were looking for sales of $174.1 million.
“Omnicell completed a strong second quarter marked by record revenues and earnings results ahead of expectations,” chairman, president & CEO Randall Lipps said in prepared remarks. “We are proud of the company’s financial performance and our strategic execution aimed at supporting health systems in achieving their patient safety, operational and financial goals.”
“I am particularly pleased by the momentum and broad adoption of our recent innovations, including the XT series,” he added. “I believe we are positioned well for continued success in the future.”
OMCL shares were trading at $48.35 apiece today in afternoon activity, up 13%.